{"id":"buspirone-alprazolam","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness/sedation"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dependence/withdrawal risk (alprazolam component)"},{"rate":null,"effect":"Cognitive impairment"}]},"_chembl":{"chemblId":"CHEMBL661","moleculeType":"Small molecule","molecularWeight":"308.77"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buspirone selectively binds to serotonin 5-HT1A receptors, modulating serotonergic neurotransmission to reduce anxiety without sedation or muscle relaxation. Alprazolam enhances GABAergic inhibitory neurotransmission by potentiating GABA-A receptors, producing rapid anxiolytic, sedative, and muscle-relaxant effects. The combination leverages both mechanisms for broader anxiety symptom coverage.","oneSentence":"This combination pairs a serotonin 5-HT1A receptor agonist (buspirone) with a benzodiazepine GABA-A receptor agonist (alprazolam) to enhance anxiolytic effects through dual pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:41:26.391Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anxiety disorders (generalized anxiety disorder, panic disorder)"},{"name":"Short-term anxiety management"}]},"trialDetails":[{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT01546896","phase":"PHASE4","title":"Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder","status":"WITHDRAWN","sponsor":"Seoul National University Hospital","startDate":"2012-03","conditions":"Anxiety Disorder","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"buspirone+alprazolam","genericName":"buspirone+alprazolam","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination pairs a serotonin 5-HT1A receptor agonist (buspirone) with a benzodiazepine GABA-A receptor agonist (alprazolam) to enhance anxiolytic effects through dual pathways. Used for Anxiety disorders (generalized anxiety disorder, panic disorder), Short-term anxiety management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}